• Canaccord Genuity sets a price target of $50 for NASDAQ:CSTL, indicating a potential upside of 26.77%.
• Insider Derek Maetzold sells 509 shares, reducing his holdings by 1.46%.
• Castle Biosciences exhibits strong liquidity with a quick ratio of 6.31 and a minimal debt-to-equity ratio of 0.02.

Castle Biosciences, Inc. (NASDAQ: CSTL) is a company that specializes in providing diagnostic and prognostic tests for dermatologic cancers. On December 22, 2025, Canaccord Genuity set a price target of $50 for CSTL, suggesting a potential upside of 26.77% from its current trading price of $39.44. This optimistic outlook comes despite recent insider selling activity.

Derek Maetzold, an insider at Castle Biosciences, sold 509 shares on December 17th at an average price of $40.04, totaling $20,380. This sale reduced his holdings by 1.46%, leaving him with 34,360 shares valued at approximately $1.38 million. Such insider activity can sometimes signal confidence or concern about the company's future performance.

Castle Biosciences' stock opened at $39.44, reflecting a slight decrease of 0.4%. Over the past year, the stock has fluctuated between a low of $14.59 and a high of $40.61. The company's market capitalization is $1.15 billion.

Castle Biosciences maintains a strong liquidity position. The company has a quick ratio of 6.31 and a current ratio of 6.47, suggesting it can easily cover its short-term liabilities. Additionally, the company has a minimal debt-to-equity ratio of 0.02, indicating low financial leverage.

The stock's beta of 1.14 suggests that it is slightly more volatile than the market. With a trading volume of 361,576 shares, CSTL remains actively traded. As highlighted by TheFly, the recent price target set by Canaccord Genuity reflects a positive outlook for the company's future, despite recent insider selling and current market conditions.